|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Kaplan-Meier survival analysis showed that the survival time of all the patients with high IGFBP2 tumors had shorter survival than those with low IGFBP2 (<i>P</i><0.01).
|
31138764 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Blocking IGFBP2 suppressed tumor growth and improved survival of tumor bearing mice in the mouse GBM model.
|
31560714 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, it is urgent to thoroughly investigate the immune biological process of IGFBP2 to understand tumor immune complexity and provide potential evidence for anti-IGFBP2 therapy.
|
29721393 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IGFBP-2 also mediates tumor cell growth, invasion and resistance, while the mechanisms remain unclear.
|
28977895 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Insulin-like growth factor binding protein 2 (IGFBP2) binds insulin, IGF1 and IGF2 in circulation, thereby modulating cell survival, migration, and invasion in neoplasms.
|
28410230 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mechanistic investigations defined insulin-like growth factor binding protein 2 as a direct and functional downstream target of microRNA-592, which was involved in the microRNA-592-mediated tumor-suppressive effects in glioma cells.
|
28718372 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The contributions of intracellular IGFBP2 to tumor development and progression are also unclear.
|
25893308 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The markers significantly overexpressed already in earlier tumor stages (pT1-2) of both histological subtypes (n = 19) have been clustered in a "diagnostic signature": PLA2G7, PRAME, MMP1, MMP3, MMP12, LIlRB2, TREM2, CHST2, IGFBP2, IGFBP7, KCNJ8, EMILIN2, CTHRC1, EMR2, WDR72, LPCAT1, COL4A2, CCL4, and SNX10.
|
26631031 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The studies presented here indicate that IGFBP2 not only is a driver of glioma progression and a prognostic factor but is also required for tumour maintenance and thus represents a viable therapeutic target in the treatment of glioma.
|
27125842 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results suggest that targeted inhibition of IGFBP2 alone or together with either the MAPK or PI3K/AKT signaling pathway in IGFBP2-overexpressing EAC tumors may be an effective approach for sensitizing resistant EACs to standard neoadjuvant chemotherapy.
|
26317790 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immune monitoring posttreatment showed an increase in effector T cells recognizing the tumor antigens IGFBP2 and FRα, indicating that MV-NIS treatment triggered cellular immunity against the patients' tumor and suggesting that an immune mechanism mediating the observed antitumor effect.
|
25398436 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Besides a high level of big IGF-II, patient's plasma also contained increased levels of both IGFBP-2 and -6 which declined after removal of the tumor.
|
26073062 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
By removing protease cleavage and matrix-binding sites, modified IGFBP-2 was effective in inhibiting tumour growth and reducing tumour angiogenesis.
|
24853186 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We also investigated the expression of IGFBP2 in microvesicles (MVs) collected from primary lung cancer cell cultures, and in different locations of newly resected NSCLC tumors, using immunoblotting.
|
24682597 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ANOVA tests showed that the difference of mean ΔCt for IGFBP2 gene between healthy subjects and patients with HCMV-positive and HCMV-negative glioblastoma tumors statistically significant.
|
24352760 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A multivariate analysis showed that lung cancer patients whose blood IGFBP2 was higher than 160.9 ng/ml had a poor survival outcome, with a hazard ratio of 8.76 (95% CI 1.12-68.34, p=0.038 after adjustment for tumor size, pathology, and stage).
|
24069370 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Elevated expression of IGFBP2 is associated with progression of tumors that include prostate, ovarian, glioma among others.
|
23767917 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Class 1 tumors had elevated EZH2 expression but not elevated IGFBP2; class 2 tumors had both high IGFBP2 and high EZH2 expressions.
|
21339190 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High IGFBP2 expression correlates with tumor severity in pediatric rhabdomyosarcoma.
|
21924226 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IGFBP2 promotes glioma tumor stem cell expansion and survival.
|
20515648 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Insulin-like growth factor binding protein 2 (IGFBP-2) has been implicated in the pathophysiology of neoplasia.
|
20370577 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results demonstrate for the first time in an experimental model that IGFBP-2 overabundance prior to the onset and during colorectal carcinogenesis reduces tumor growth by inhibition of cell proliferation.
|
19142966 |
2009 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Stable expression of K18Y-TATI in HT-29 5M21 cells downregulated tumor growth, angiogenesis and the expression of several metastasis-related genes, including CSPG4 (13.8-fold), BMP-7 (9.7-fold), the BMP antagonist CHORDIN (5.2-fold), IGFBP-2 and IGF2 (9.6- and 4.6-fold).
|
18317448 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our studies show that IGFBP2 coexpression results in progression to a higher-grade glioma in platelet-derived growth factor beta (PDGFB)-driven tumors.
|
17606927 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
EGFR, IGFBP-2 and HIF-2A gene expression levels were analyzed by quantitative real-time PCR and differed significantly between grades I-IV astrocytic tumors (P < 0.0001, P < 0.0001 and P: 0.0013, respectively) when analyzed by the Kruskal-Wallis test.
|
17285230 |
2007 |